Asthma Clinical Trial
Official title:
Pivotal Study of the Performance and Safety of the Pneumoscope Device in Adults and Children
Respiratory diseases are associated with high morbidity and mortality worldwide. Proper diagnosis and risk assessment of these conditions are essential for optimal management. Clinicians use three particularly useful tools to identify these conditions when assessing the patient's status: the stethoscope, the pulse oximeter, and the thermometer. The Pneumoscope is an all-in-one device including a digital stethoscope, a pulse oximeter, and a thermometer. This study aims to assess the performance and safety of the Pneumoscope in recording respiratory sounds, body temperature, non-invasive blood oxygen saturation levels and heart rate in children and adults.
Status | Not yet recruiting |
Enrollment | 225 |
Est. completion date | December 31, 2024 |
Est. primary completion date | December 31, 2024 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 1 Year and older |
Eligibility | Patients will be recruited from the pediatric and adult clinical departments of the Geneva University Hospitals. Inclusion Criteria: - Age > 1 year old. - Healthy patients on the day of auscultation OR - Patients with lower respiratory tract diseases (e.g., bronchitis, pneumonia, etc.). OR - Patients with low (i.e., <92%) pulse oximetry values (e.g., cyanotic heart defect such as tetralogy of Fallot, transposition of great vessels, etc.). AND / OR - Patients with fever >38.0°C. - And for all: Information and written consent of the patient or a legal representative. Exclusion Criteria: - Refusal of consent. - Clinical signs of severity: acute hypoxia, hypercapnia, acute respiratory failure, acute circulatory failure. - Immune disorder, primary ciliary dyskinesia, antecedent of neonatal bronchopulmonary dysplasia. - Contraindications and limitations of the MD as described in the instructions for use. - Contraindications to the class of medical devices being studied, e.g. known hypersensitivity or allergy to the device material. - Clinically significant concomitant disease states. - Inability to follow the study procedures, e.g. due to language problems, psychological disorders, dementia, etc. - Participation in another study with an investigational drug or other medical device within 30 days prior to and during the present study. |
Country | Name | City | State |
---|---|---|---|
Switzerland | Geneva University Hospitals | Geneva |
Lead Sponsor | Collaborator |
---|---|
Pediatric Clinical Research Platform | University Hospital, Geneva |
Switzerland,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Evaluation of Pneumoscope's built-in sensors | To be used in patients and certified by competent authorities the performance of Pneumoscope has to be at least equal as comparable devices on the market. Performances of digital audio quality, as well as pulse oximetry, heart rate and temperature measurements by the Pneumoscope will be compared to CE certified similar medical devices used as gold-standards tools. Hence, the primary objective is to evaluate whether the three built-in sensors into the Pneumoscope are equivalent to CE marked Gold Standards:
Spectral comparison and other audio quality indices of recordings with the Pneumoscope and a commercially available digital stethoscope (Littmann® CORE digital stethoscope). Agreement between the Pneumoscope thermometer and reference thermometers (Terumo® C205 and VisioFocus Pro® 06480). Agreement between the Pneumoscope pulse oximeter (for blood oxygen saturation and heart rate) and reference oximeters (Masimo Rad-G® and iHealth® Air). |
During procedure, i.e. 20 minutes per patient for both out- and inpatients. | |
Secondary | Collect audio records of lung sounds for AI models training and sensor calibration | The collected anonymised audio records of lung sounds will be used in the future to develop and validate AI algorithms for various bronchopulmonary diseases in children (pneumonia, asthma, bronchiolitis), as well as SARS-CoV-2 infections in adults. | During procedure, i.e. 20 minutes per patient for both out- and inpatients. | |
Secondary | Pulse oximetry | The collected pulse oximetry measures will be used to calibrate the oximeter sensor. | During procedure, i.e. 20 minutes per patient for both out- and inpatients. | |
Secondary | Body temperature | The collected, non-invasive, body temperature measures will be used to calibrate the thermometer sensor. | During procedure, i.e. 20 minutes per patient for both out- and inpatients. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04624425 -
Additional Effects of Segmental Breathing In Asthma
|
N/A | |
Terminated |
NCT04410523 -
Study of Efficacy and Safety of CSJ117 in Patients With Severe Uncontrolled Asthma
|
Phase 2 | |
Active, not recruiting |
NCT03927820 -
A Pharmacist-Led Intervention to Increase Inhaler Access and Reduce Hospital Readmissions (PILLAR)
|
N/A | |
Completed |
NCT04617015 -
Defining and Treating Depression-related Asthma
|
Early Phase 1 | |
Recruiting |
NCT03694158 -
Investigating Dupilumab's Effect in Asthma by Genotype
|
Phase 4 | |
Terminated |
NCT04946318 -
Study of Safety of CSJ117 in Participants With Moderate to Severe Uncontrolled Asthma
|
Phase 2 | |
Completed |
NCT04450108 -
Vivatmo Pro™ for Fractional Exhaled Nitric Oxide (FeNO) Monitoring in U.S. Asthmatic Patients
|
N/A | |
Completed |
NCT03086460 -
A Dose Ranging Study With CHF 1531 in Subjects With Asthma (FLASH)
|
Phase 2 | |
Completed |
NCT01160224 -
Oral GW766944 (Oral CCR3 Antagonist)
|
Phase 2 | |
Completed |
NCT03186209 -
Efficacy and Safety Study of Benralizumab in Patients With Uncontrolled Asthma on Medium to High Dose Inhaled Corticosteroid Plus LABA (MIRACLE)
|
Phase 3 | |
Completed |
NCT02502734 -
Effect of Inhaled Fluticasone Furoate on Short-term Growth in Paediatric Subjects With Asthma
|
Phase 3 | |
Completed |
NCT01715844 -
L-Citrulline Supplementation Pilot Study for Overweight Late Onset Asthmatics
|
Phase 1 | |
Terminated |
NCT04993443 -
First-In-Human Study to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of LQ036
|
Phase 1 | |
Completed |
NCT02787863 -
Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology
|
Phase 4 | |
Recruiting |
NCT06033833 -
Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study
|
Phase 2 | |
Completed |
NCT03257995 -
Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Two Orally Inhaled Indacaterol Salts in Adult Subjects With Asthma.
|
Phase 2 | |
Completed |
NCT02212483 -
Clinical Effectiveness and Economical Impact of Medical Indoor Environment Counselors Visiting Homes of Asthma Patients
|
N/A | |
Recruiting |
NCT04872309 -
MUlti-nuclear MR Imaging Investigation of Respiratory Disease-associated CHanges in Lung Physiology
|
||
Withdrawn |
NCT01468805 -
Childhood Asthma Reduction Study
|
N/A | |
Recruiting |
NCT05145894 -
Differentiation of Asthma/COPD Exacerbation and Stable State Using Automated Lung Sound Analysis With LungPass Device
|